ATS targets 15% EBIT margin after Q1 revenue miss
ATS Corporation is aiming to restore its long-term operating margin to 15%, with about half of the improvement expected from fixed-cost reductions. In the first quarter of fiscal 2027, revenue was C$693.7 million, below the C$724.0 million consensus. The stock closed at $19.10 on Sept. 25, 2026, near its 52-week low, while analysts have mixed views and several price-target cuts.
ATS reported fiscal 2027 first-quarter revenue of C$693.7 million, missing the C$724.0 million FactSet consensus by C$30.3 million. The quarter ended June 28, 2026, and MarketScreener published the figures on Sept. 3, 2026. Management's margin plan calls for roughly half of the improvement to come from lower fixed costs, with aftermarket growth, the ATS Business Model, and supply-chain work supplying the rest.
Life sciences account for half of the portfolio, while 80% of backlog comes from heavily regulated sectors, according to Investing.com's Sept. 10, 2026 report on the Jefferies conference transcript. Analyst views are mixed: MarketBeat cited a Moderate Buy consensus and C$42.25 average target on Sept. 6, 2026, while Raymond James, Stifel, and TD all cut targets.
ATS's push to restore a 15% EBIT margin, partly through fixed-cost reductions, could affect employees, suppliers, and customers in regulated life-sciences markets. If cost cuts are implemented carefully, service continuity may be preserved; if not, execution risks could disrupt customer operations. Investors may face continued volatility after the revenue miss and target cuts. Broader effects on innovation or equipment access remain uncertain and may depend on how management balances efficiency with long-term customer relationships.